Caffeine increases POAG risk

Article

High caffeine intake is associated with an increased risk of high-tension primary open angle glaucoma (POAG) in subjects with a positive family history of glaucoma, according to a study published in the May 2008 issue of Investigative Ophthalmology & Visual Science.

High caffeine intake is associated with an increased risk of high-tension primary open angle glaucoma (POAG) in subjects with a positive family history of glaucoma, according to a study published in the May 2008 issue of Investigative Ophthalmology & Visual Science.

Jae Hee Kang, ScD of Harvard Medical School, US and colleagues observed subjects aged ≥40 years without POAG to determine if caffeine, which raises intraocular pressure (IOP), is also associated with an increased risk of POAG.

Of the 121,172 subjects monitored and followed-up with questionnaires between 1980 and 2004, 1011 POAG cases were confirmed. The researchers found that higher levels of caffeinated coffee intake correlated with increased risk of POAG, particularly POAG with elevated IOP, in those with a family history of glaucoma.

Compared with an intake of ≤150 mg/day, consumption of 150–299 mg/d was associated with a 1.05 increased risk; for 300–449 mg/d, risk increased 1.19 times; consuming 450–599 mg/d carried a 1.13 greater risk; for ≥600 mg/d, risk increased 1.17 times. Where ≥5 cups of caffeinated coffee were consumed daily, the risk was 1.61 times greater. Consumption of tea and caffeinated cola did not correlate with an increased risk.

Greater caffeine intake was associated with elevated POAG risk only in those with positive family histories of glaucoma. The researchers concluded that these results warrant further study, as the apparent increased risk may be an accident of chance rather than a concrete correlation.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.